

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: ISPH-0765
Inventors: Graham and Watt
Serial No.: Not Yet Assigned
Filing Date: Herewith
Examiner: Not Yet Assigned
Group Art Unit: Not Yet Assigned
Title: Antisense Modulation of Complement
Component C3 Expression

"Express Mail" Label No. EL976562822US
Date of Deposit August 18, 2003

I hereby certify that this paper is being deposited
with the United States Postal Service "Express Mail
Post Office to Addressee" service under 37 CFR 1.10
on the date indicated above and is addressed to the
Commissioner for Patents, Mail Stop Sequence, P. O.
Box 1450, Alexandria, VA 22313-1450.

By Jane Massey Licata
Typed Name: Jane Massey Licata, Reg. No. 32,257

Commissioner for Patents
Mail Stop Sequence
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

- (XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.
- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
- () Certification in Accordance with §1.97(e) is set forth below; or
- () The fee of \$180.00 as set forth in §1.17(p) is attached.
- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).
- () Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.


(XX) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. 10/001,076, filed October 23, 2001 for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,



Jane Massey Licata
Registration No. 32,257

Date: August 18, 2003

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

Form PTO-1449 Modified		Docket No. ISPH-0765	Serial No. not yet assigned
List of Patents and Publications Cited by Application (Use several sheets if necessary)		Applicant Mark J. Graham et al.	
		Filing Date herewith	Group
U.S. Department of Commerce Patent and Trademark Office			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Carroll, <i>The role of complement and complement receptors in induction and regulation of immunity</i> , <i>Annu. Rev. Immunol.</i> , 1998 , 16:545-568	
	AB	de Bruijn et al., <i>Human complement component C3: cDNA coding sequence and derived primary structure</i> , <i>Proc. Natl. Acad. Sci. U. S. A.</i> , 1985 , 82:708-712	
	AC	Fong et al., <i>Genomic organization of human complement component C3</i> , <i>Genomics</i> , 1990 , 7:579-586	
	AD	Kirschfink, <i>Controlling the complement system in inflammation</i> , <i>Immunopharmacology</i> , 1997 , 38:51-62	
	AE	Mabbott et al., <i>Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie</i> , <i>Nat. Med.</i> , 2001 , 7:485-487	
	AF	Muscari et al., <i>Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged men</i> , <i>Eur. Heart J.</i> , 2000 , 21:1081-1090	
	AG	Nataf et al., <i>Attenuation of experimental autoimmune demyelination in complement-deficient mice</i> , <i>J. Immunol.</i> , 2000 , 165:5867-5873	
	AH	Whitehead et al., <i>Assignment of the structural gene for the third component of human complement to chromosome 19</i> , <i>Proc. Natl. Acad. Sci. U. S. A.</i> , 1982 , 79:5021-5025	
	AI	Yudkin, <i>Relationship of serum C3 complement with insulin resistance and coronary heart disease-cause, consequence or common antecedent?</i> , <i>Eur. Heart J.</i> , 2000 , 21:1036-1039	
EXAMINER		DATE CONSIDERED	

DOCKET NO.: ISPH-0765

Form PTO-1449 Modified	Docket No. ISPH-0765	Serial No.
List of Patents and Publications Cited by Application (Use several sheets if necessary)	Applicant Mark J. Graham et al.	
U.S. Department of Commerce Patent and Trademark Office	Filing Date	Group

U.S. PATENT DOCUMENTS

Examiner's Initial		Document No.	Date	Name	Class	Subclass
	AA	6,221,657	04/24/2001	Harrison et al.	435	320.1
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					

FOREIGN PATENT DOCUMENTS

Examiner's Initial		Document No.	Date	Country	Translation YES NO	
	AO	WO 97/32981	04/03/1997	PCT	X	
	AP					
	AQ					
	AR					
	AS					
	AT					
	AU					
	AV					
	AW					
	AX					

EXAMINER

DATE CONSIDERED